TY - JOUR
T1 - Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test
T2 - Who Should Be Tested? Who Should Not?
AU - Viskin, Sami
AU - Chorin, Ehud
AU - Rosso, Raphael
AU - Amin, Ahmad S.
AU - Wilde, Arthur A.
N1 - Publisher Copyright:
© 2024 American Heart Association, Inc.
PY - 2024/8/20
Y1 - 2024/8/20
N2 - Intravenous infusion of sodium-channel blockers (SCB) with either ajmaline, flecainide, procainamide, or pilsicainide to unmask the ECG of Brugada syndrome is the drug challenge most commonly used for diagnostic purposes when investigating cases possibly related to inherited arrhythmia syndromes. For a patient undergoing an SCB challenge, the impact of a positive result goes well beyond its diagnostic implications. It is, therefore, appropriate to question who should undergo a SCB test to diagnose or exclude Brugada syndrome and, perhaps more importantly, who should not. We present a critical review of the benefits and drawbacks of the SCB challenge when performed in cardiac arrest survivors, patients presenting with syncope, family members of probands with confirmed Brugada syndrome, and asymptomatic patients with suspicious ECG.
AB - Intravenous infusion of sodium-channel blockers (SCB) with either ajmaline, flecainide, procainamide, or pilsicainide to unmask the ECG of Brugada syndrome is the drug challenge most commonly used for diagnostic purposes when investigating cases possibly related to inherited arrhythmia syndromes. For a patient undergoing an SCB challenge, the impact of a positive result goes well beyond its diagnostic implications. It is, therefore, appropriate to question who should undergo a SCB test to diagnose or exclude Brugada syndrome and, perhaps more importantly, who should not. We present a critical review of the benefits and drawbacks of the SCB challenge when performed in cardiac arrest survivors, patients presenting with syncope, family members of probands with confirmed Brugada syndrome, and asymptomatic patients with suspicious ECG.
KW - Brugada syndrome
KW - ajmaline
KW - flecainide
KW - procainamide
KW - sodium channel blockers
KW - ventricular fibrillation
UR - http://www.scopus.com/inward/record.url?scp=85201741749&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.124.069138
DO - 10.1161/CIRCULATIONAHA.124.069138
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 39159224
AN - SCOPUS:85201741749
SN - 0009-7322
VL - 150
SP - 642
EP - 650
JO - Circulation
JF - Circulation
IS - 8
ER -